Advertisements



Ardelyx IBS-C Candidate Succeeds in Pivotal Study, Stock Up

Ardelyx's (ARDX) tenapanor reduces abdominal pain and improves bowel movements in a phase III study evaluating the drug in irritable bowel syndrome with constipation. Ar.....»»

Category: personnelSource: nytOct 12th, 2017

AbbVie Psoriasis Candidate Succeeds in 4th Phase III Study

AbbVie (ABBV) announces data from a phase III study on risankizumab, which shows that a significant portion of plaque psoriasis patients treated with risankizumab achieved high levels of skin clearance. AbbVie, Inc. AB.....»»

Category: personnelSource: nytDec 5th, 2017

Immune Design"s Sarcoma Candidate to Enter Phase III in 2018

Immune Design (IMDZ) plans to initiate a pivotal phase III study to support a Biologics License Application (BLA) for CMB305. .....»»

Category: personnelSource: nytOct 17th, 2017

30 Stocks Moving In Thursday"s Pre-Market Session

Gainers Ardelyx Inc (NASDAQ: ARDX) rose 44.4 percent to $7.80 in pre-market trading after the company disclosed that its pivotal Phase 3 study of tenapanor hit primary and all secondary endpoints. read more.....»»

Category: blogSource: benzingaOct 12th, 2017

Nabriva"s Lefamulin Positive in Pivotal Study, Stock Surges

Nabriva Therapeutics' (NBRV) lefamulin sh.....»»

Category: dealsSource: nytSep 19th, 2017

Down 13.69%: Is Sage Therapeutics Stock a Bad-News Buy?

Sage's lead drug candidate whiffs in a late-stage study......»»

Category: topSource: foxnewsSep 12th, 2017

Why this Peninsula biotech"s stock is soaring

The South San Francisco company will ask the FDA if "encouraging" results from a mid-stage study — powering an 88 percent leap in its stock price — is enough to jump into a pivotal Phase III trial......»»

Category: topSource: bizjournalsAug 7th, 2017

Indivor"s Opioid Use Disorder Drug Meets Primary Endpoint

Indivior PLC (INVVY) announced that a pivotal study (RB-US-13-0001) evaluating its candidate, RBP-6000, in patients with moderate-to-severe o.....»»

Category: topSource: zacksJun 22nd, 2017

Teva Migraine Candidate Succeeds in Second Phase III Study

Teva announced that its experimental migraine prevention candidate.....»»

Category: topSource: zacksJun 8th, 2017

Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses in Pivotal Study

While companies like Mylan (MYL), Allergan and Teva reported Q1 results this week, several companies provided updates on their cancer drugs. This week, companies like Mylan MY.....»»

Category: topSource: zacksMay 12th, 2017

Ultragenyx"s Hypophosphatemia Drug Succeeds in Phase III

Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Hakko Kirin Co., Ltd announced positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with X-linked.....»»

Category: topSource: zacksApr 19th, 2017

Heat Biologics Stock Falls on Negative Bladder Cancer Data

Heat Biologics (HTBX) presented disappointing top-line phase II data from the bladder cancer study on its lead pipeline candidate, HS-410. Heat Biologics, Inc.’s HTBX shares plunged 56.1% during yesterday’s after-hours trading afte.....»»

Category: topSource: zacksDec 1st, 2016

Lilly"s Alzheimer Drug Fails Phase III Study, Stock Down

Lilly's Eli Lilly and Company (LLY) announced that its key pipeline candidate, solanezumab, failed to meet the primary endpoint in a phase III study (EXPEDITION3) in patients with mild Alzheimer's dementia. Lilly’s Eli Lilly and Company L.....»»

Category: topSource: zacksNov 24th, 2016

Amgen Presents Osteoporosis Data; Parsabiv Approved in EU

Amgen, Inc. (AMGN) and partner UCB S.A. (UCBJF) announced results from the pivotal phase III BRIDGE study which showed that its pipeline candidate, romosozumab, significantly increases bone mineral density in men with osteoporosis. Amgen, Inc. .....»»

Category: topSource: zacksNov 14th, 2016

Why Celldex Therapeutics, Inc. Stock Sank 28.1% in August

Further delays for its lead candidate's pivotal trial gave investors reasons to be nervous......»»

Category: topSource: foxnewsSep 12th, 2016

Lexicon Pharmaceuticals, Sanofi Collab Sotagliflozin Outshines in Phase 3 Diabetes Trial

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock jumped as high as 24.89% during the early trading hours today, after the company reported the results from its pivotal inTandem1 Phase 3 trial of Sotagliflozin, which is a treatment for diabetes. The study.....»»

Category: topSource: bidnessetcSep 9th, 2016

Lexicon Pharmaceuticals, Inc, Sanofi SA Collab Sotagliflozin Outshines in Phase 3 Diabetes Trial

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock jumped as high as 24.89% during the early trading hours today, after the company reported the results from its pivotal inTandem1 Phase 3 trial of Sotagliflozin, which is a treatment for diabetes. The study.....»»

Category: topSource: bidnessetcSep 9th, 2016

CoLucid Stock Skyrockets on Positive Results from Phase 3 SAMURAI Study

CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) today announced that its SAMURAI Phase 3 pivotal trial of lasmiditan, which aims to treat migraine, has achieved the primary and secondary efficacy endpoints with statistical significance (p < 0.001). According t.....»»

Category: topSource: bidnessetcSep 6th, 2016

Roche/AbbVie Report Positive Phase III Results on Venclexta

Roche (RHHBY) announced positive results from a pivotal phase III study, MURANO, evaluating Venclexta plus Ri.....»»

Category: personnelSource: nytDec 13th, 2017

Novartis Announces Positive Data on Sickle Cell Disease Drug

Novartis (NVS) announced positive data from a phase II study, SUSTAIN, on pipeline candidate crizanlizumab which deferred the time to first s.....»»

Category: worldSource: nytDec 12th, 2017

Juno Reports Additional Data on CAR-T Therapy, Shares Drop

Juno (JUNO) releases additional results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate, JCAR017. Juno Therapeutics, Inc. JUNO along with partner Celgene Corporation CE.....»»

Category: worldSource: nytDec 12th, 2017